Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.42 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CCR2 | P41597 | 3/20 | 0.39 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3887750 | 0.80 | MEN1 (0.43) | MAPTMEN1LMNAKMT2AP2RX1 | |
| SCHEMBL3888543 | 0.78 | EPHX2 (0.38) | MAPTMEN1KMT2ARAB9AP2RX1 | |
| SCHEMBL20836623 | 0.73 | MAPT (0.41) | MAPTP2RX1EPHX1 | |
| SCHEMBL4300746 | 0.67 | MAPT (0.44) | MAPTRAB9AP2RX1ALDH1A1CCR2 | |
| SCHEMBL3895059 | 0.67 | CCR2 (0.82) | CCR2 | |
| SCHEMBL3895062 | 0.67 | CCR2 (0.82) | CCR2 | |
| SCHEMBL3895054 | 0.67 | CCR2 (0.82) | CCR2 | |
| SCHEMBL6693442 | 0.67 | PTPRF (0.59) | MAPTMEN1LMNAKMT2AKDM4E | |
| SCHEMBL11010708 | 0.66 | P2RX1 (0.58) | MAPTMEN1LMNAKMT2ANPC1 | |
| SCHEMBL28217527 | 0.66 | P2RX1 (0.68) | MAPTMEN1LMNAKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334405-B2 | Chiral thiourea compounds and process for enantioselective reduction of ketones | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-12-18 | — | — | US | claimed |
| US-8334405-B2 | Chiral thiourea compounds and process for enantioselective reduction of ketones | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-12-18 | — | — | US | disclosed |
| US-20090253919-A1 | Chiral thiourea compounds and process for enantioselective reduction of ketones | BOARD OF REGENTS (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253919-A1 | Chiral thiourea compounds and process for enantioselective reduction of ketones | TREH, ADH1A, ADH1C | MAPT 3969/4885MEN1 4127/4885LMNA 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.